Hormonal
GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.
If you take a GLP-1 medication along with insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) increases. However, this risk is still lower than if you were taking insulin or sulfonylureas alone. Monitor your blood sugar as advised by your doctor.
A systematic review of 34 trials involving 14 464 participants found that most GLP-1RAs (except Albiglutide) were associated with increased hypoglycemia rates (10.4%-19.4%) compared with placebo. Nevertheless, the risk remains lower than that associated with sulfonylureas or insulin therapy.
Why this rating
Based on a systematic review of 34 trials cited within the bibliometric analysis.
Source
Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis
Riad Mohammed Abdelrahman et al. · INQUIRY The Journal of Health Care Organization Provision and Financing · 2026
DOI 10.1177/00469580261441498
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.Good
- GLP-1RAs are associated with rare but serious adverse events including acute pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, though causal relationships for some (like thyroid cancer) are not confirmed in humans.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →